U.S.stocks closed higher on Thursday at August highs despite subpar economic data around the world, and after conciliatory remarks from Putin.» Read More
Amgen Inc. rose$. 68 or. 5 percent, to $126.43. Biogen Idec rose $2.73 or. 9 percent, to $323.33. Celgene Corp. rose$. 75 or. 9 percent, to $85.97.
Amgen Inc. rose$. 24 or. 2 percent, to $125.99. Biogen Idec rose $2.04 or. 6 percent, to $322.64. Celgene Corp. rose$. 42 or. 5 percent, to $85.64.
Using the CNBC RQ 50 measure for R&D productivity, we've identified an elite group of companies that merit election to an R&D hall of fame.
Aug 5- Regeneron Pharmaceuticals Inc on Tuesday reported higher-than-expected quarterly revenue and earnings on surging demand for its Eylea treatment for macular degeneration, and stuck to its full-year sales forecast for the drug.
Cramer likes to review the S&P 500’s Daily Action Charts in an effort to find stocks that could work higher.
*Berkshire Hathaway shares up after results. NEW YORK, Aug 4- U.S. stocks were slightly positive in trading on Monday afternoon, boosted by earnings including Berkshire Hathaway's results, though gains were offset by drops in high-dividend payers in the utilities sector.
Some of Monday's midday movers:
*Berkshire Hathaway shares up after results. NEW YORK, Aug 4- U.S. stocks were little changed in volatile trading Monday as earnings, including those of Warren Buffett's Berkshire Hathaway, were partly offset by drops in high-yielding dividend stocks in the utilities sector.
*Advair restored to Express Scripts 2015 formulary list. LONDON, Aug 4- GlaxoSmithKline received a boost on Monday from a decision by Express Scripts, the largest U.S. pharmacy benefit manager, to reinstate its top-selling lung drug Advair as an approved drug in 2015..
*Berkshire Hathaway shares up after results. *Michael Kors shares reverse premarket move, fall 5.5 pct. NEW YORK, Aug 4- U.S. stocks rose in morning trading on Monday, lifted by earnings including those of Warren Buffett's Berkshire Hathaway, with gains partly offset by drops in high-yielding dividend stocks in the utilities sector.
Aug 4- Amgen Inc said a late-stage study found that its blood cancer drug helped patients live significantly longer without the disease worsening, compared with standard treatment. The data may support the conversion of accelerated approval to full approval and help the company expand the current indication in the United States, Amgen said.
Aug 4- Amgen Inc said its cancer drug significantly improved the length of time that patients lived with a type of blood cancer without the disease worsening. Amgen's share rose 4.3 percent to $130.96 in premarket trading on Monday after the company released the interim data from a late-stage study.
Some of the names on the move ahead of the open.
Aug 1- Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc..
PARIS, July 31- French drugmaker Sanofi raised its full-year profit forecast on Thursday along with a set of stronger than expected quarterly earnings driven by its rare disease and diabetes businesses and higher sales in emerging markets.
*Twitter shares rally a day after results. Among the biggest positives were bank shares, with the S&P financial index up 0.4 percent, helping to support the S&P 500. Shares of Wells Fargo gained 1.1 percent to $52.10.
NEW YORK, July 30- The S&P 500 was near flat on Wednesday after the Federal Reserve gave a rosier assessment of the U.S. economy while reaffirming that it is in no hurry to raise interest rates.
*Twitter rallies after blockbuster results. NEW YORK, July 30- U.S. stocks were flat on Wednesday, paring earlier gains as a strong read on second-quarter economic growth sparked concerns the Federal Reserve may adjust its stimulus earlier than expected.
*Twitter rallies after blockbuster results. *Biotechs rally on Amgen results, Regeneron trial data. Twitter Inc surged on heavy volume, jumping 25 percent to $48.25 in its biggest one-day advance ever after reporting that monthly active users had risen a better-than-expected 24 percent in the second quarter.
CNBC's Jim Cramer on Wednesday identified two biotechnology stocks that he thinks could climb.